Circulating angiotensinogen

1. Hepatic angiotensinogen-lowering RNA therapeutics decrease circulating angiotensinogen in humans (hypertension; versus control) (MD –66.82%; 95% CI –92.71 to –40.92).

   “Circulating AGT was also significantly reduced (MD –66.82%; 95% CI –92.71 to –40.92).”

   Reviewhypertension; versus control

   Hepatic Angiotensinogen-Lowering RNA Therapeutics for Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

   AHA Scientific Sessions 2026 abstract·Nov 2, 2026

More on Hepatic angiotensinogen-lowering RNA therapeutics

1. Zilebesiran decreases circulating angiotensinogen in humans (hypertension).

   “Zilebesiran has demonstrated sustained reductions in circulating angiotensinogen and ambulatory blood pressure following infrequent subcutaneous administration in phase 1 and phase 2 clinical trials.”

   Reviewhypertension

   Are Injectable Antihypertensives the Answer to Improving Blood Pressure Control: SiRNAs and Antisense Oligonucleotide Agents

   Current cardiology reports·Oct 29, 2026

More on Zilebesiran